Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed the day trading at $1.09 up 0.93% from the previous closing price of $1.08. In other words, the price has increased by $+0.0100 from its previous closing price. On the day, 21091584 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of DNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Dmytruk Mark E. sold 38,826 shares for $1.26 per share. The transaction valued at 48,765 led to the insider holds 808,125 shares of the business.
Dmytruk Mark E. sold 39,569 shares of DNA for $47,799 on Feb 02 ’24. The insider now owns 761,737 shares after completing the transaction at $1.21 per share. On Jan 04 ’24, another insider, Kelly Jason R, who serves as the insider of the company, sold 100,000 shares for $1.55 each. As a result, the insider received 155,500 and left with 3,894,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 2.35B and an Enterprise Value of 1.64B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.81 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 6.54 whereas that against EBITDA is -2.00.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 1.3060, while the 200-Day Moving Average is calculated to be 1.6500.
Shares Statistics:
Over the past 3-months, DNA traded about 23.17M shares per day on average, while over the past 10 days, DNA traded about 26.7M shares per day. A total of 1.53B shares are outstanding, with a floating share count of 1.34B. Insiders hold about 33.94% of the company’s shares, while institutions hold 58.12% stake in the company. Shares short for DNA as of Feb 29, 2024 were 255.72M with a Short Ratio of 11.04, compared to 236.91M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.88% and a Short% of Float of 18.83%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.1, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.28 and -$0.38 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.27, with 6 analysts recommending between -$0.21 and -$0.36.
Revenue Estimates
6 analysts predict $46.43M in revenue for the current quarter. It ranges from a high estimate of $49.93M to a low estimate of $43M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $80.7M, an estimated decrease of -42.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $53.28M, a decrease of -33.90% over than the figure of -$42.50% in the same quarter last year. There is a high estimate of $57.83M for the next quarter, whereas the lowest estimate is $50.5M.
A total of 7 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $226.92M, while the lowest revenue estimate was $217.45M, resulting in an average revenue estimate of $223.54M. In the same quarter a year ago, actual revenue was $251.46M, down -11.10% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $310.21M in the next fiscal year. The high estimate is $398.3M and the low estimate is $284.19M. The average revenue growth estimate for next year is up 38.80% from the average revenue estimate for this year.
